{"disease":{"id":"circulating-tumor-cells-ctcs","name":"circulating tumor cells ctcs"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07329920","title":"Mesenchymal CTC Ratio Dynamics Predicts Response and Survival in Pancreatic Ductal Adenocarcinoma With Neoadjuvant/Conversion Therapy","phase":"","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Guo ShiWei","has_results":false},{"nct_id":"NCT07396259","title":"Predicting Clinical Efficacy of Immunotherapy Using Pre-treatment andContinuousMonitoring of PD-L1 TPS/CPS on CTCs, and Immunity Exhaustion Scores","phase":"","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT03928210","title":"Digoxin Induced Dissolution of CTC Clusters","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"University Hospital, Basel, Switzerland","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}